Silke Gillessen and Alicia Morgans discuss the need to be proactive with bone health in this patient population. In addition, Silke shares topics that will be discussed at the 2019 Advanced Prostate Cancer Consensus Meeting (APCCC).  

Biographies:
Silke Gillessen, MD, Professor Medical Oncology, University of Berne, Switzerland. Co-founder of the Advanced Prostate Cancer Consensus Conference (APCCC)

Alicia Morgans, MD, MPH

Related Content: 

Watch: Preview of the APCCC 2019 - Interview with Silke Gillessen

The Best of Munich 2018 Congress Genitourinary Tumors, Prostate

Detailed results from the ALSYMPCA phase III study highlight the positive impact of Alpharadin (radium-223 chloride) on skeletal-related events associated with bone metastases from castration-resistant prostate cancer

Referenced in this discussion:

ERA 223 - A Phase 3 Trial of Ra-223 in Combination with Abiraterone Acetate & Prednisone for the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with mCRPC

Radiotherapy to the Primary Tumour for Men with Newly-Diagnosed Metastatic Prostate Cancer: Survival Results from STAMPEDE

Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low-Risk Metastatic Hormone Sensitive Prostate Cancer

Updated Results of GETUG-12, a Phase III Trial Of Docetaxel-Based Chemotherapy In High-Risk Localized Prostate Cancer, with a 12-Year Follow-Up